Literature DB >> 11714246

Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency.

C M Cardoso1, J B Custódio, L M Almeida, A J Moreno.   

Abstract

Tamoxifen (TAM), the widely prescribed drug in the prevention and therapy of breast cancer, is a well-known modulator of estrogen receptor (ER) that also inhibits the proliferation of different cell types that lack the ER. However, the ER-independent action mechanisms of TAM and its side effects have not been yet clarified. Mitochondria are essential in supporting the energy-dependent regulation of cell functions. Changes in mitochondria result in bioenergetic deficits leading to the loss of vital functions to cell survival. Therefore, this study describes the effects of TAM on mitochondrial bioenergetics, contributing to a better understanding of the biochemical mechanisms underlying the multiple antiproliferative and toxic effects of this drug. TAM at concentrations above 20 nmol/mg protein, preincubated with isolated rat liver mitochondria at 25 degrees C for 3 min, significantly depresses, in a dose-dependent manner, the phosphorylation efficiency of mitochondria as inferred from the decrease in the respiratory control and ADP/O ratios, the perturbations in mitochondrial transmembrane potential (DeltaPsi), the fluctuations associated with mitochondrial energization, and the phosphorylative cycle induced by ADP. Furthermore, TAM at up to 40 nmol/mg protein stimulates the rate of state 4 respiration and at higher concentrations it strongly inhibits state 3 and uncouples the mitochondrial respiration. The stimulation of state 4 respiration parallels the decrease of DeltaPsi as a consequence of proton permeability. The TAM-stimulatory action of ATPase is also observed in intact mitochondria, suggesting that TAM promotes extensive permeability to protons due to destructive effects in the structural integrity of the mitochondrial inner membrane. These multiple effects of TAM on mitochondrial bioenergetic functions, causing changes in the respiration, phosphorylation efficiency, and membrane structure, may explain the cell death induced by this drug in different cell types, its anticancer activity in ER-negative cells, and its side effects. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714246     DOI: 10.1006/taap.2001.9265

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  21 in total

1.  Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer?

Authors:  Mark M Aloysius; Abed M Zaitoun; Timothy E Bates; Mohammad Ilyas; Dumitru Constantin-Teodosiu; Brian J Rowlands; Dileep N Lobo
Journal:  BMC Cancer       Date:  2010-03-04       Impact factor: 4.430

2.  Interaction of tamoxifen and noise-induced damage to the cochlea.

Authors:  Jagan A Pillai; Jonathan H Siegel
Journal:  Hear Res       Date:  2011-09-02       Impact factor: 3.208

3.  Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline.

Authors:  Zhen Ren; Si Chen; Ji-Eun Seo; Xiaoqing Guo; Dongying Li; Baitang Ning; Lei Guo
Journal:  Toxicol In Vitro       Date:  2020-08-28       Impact factor: 3.500

4.  Harnessing gene expression to identify the genetic basis of drug resistance.

Authors:  Bo-Juen Chen; Helen C Causton; Denesy Mancenido; Noel L Goddard; Ethan O Perlstein; Dana Pe'er
Journal:  Mol Syst Biol       Date:  2009-10-13       Impact factor: 11.429

5.  The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen.

Authors:  Filomena S G Silva; Mariana P C Ribeiro; Maria S Santos; Petronila Rocha-Pereira; Alice Santos-Silva; José B A Custódio
Journal:  J Bioenerg Biomembr       Date:  2013-06-19       Impact factor: 2.945

6.  Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.

Authors:  Weiliang He; Ran Liu; Shao-Hua Yang; Fang Yuan
Journal:  Anticancer Drugs       Date:  2015-03       Impact factor: 2.248

Review 7.  Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications.

Authors:  Jin-Qiang Chen; Patrick R Cammarata; Christopher P Baines; James D Yager
Journal:  Biochim Biophys Acta       Date:  2009-06-23

Review 8.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

Review 9.  Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents.

Authors:  Mofei Huang; Charles R Myers; Yian Wang; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2020-12-10

10.  Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data.

Authors:  Kathryn J Huber-Keener; Xiuping Liu; Zhong Wang; Yaqun Wang; Willard Freeman; Song Wu; Maricarmen D Planas-Silva; Xingcong Ren; Yan Cheng; Yi Zhang; Kent Vrana; Chang-Gong Liu; Jin-Ming Yang; Rongling Wu
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.